Forest Looks to Rejuvenate with US$2.9 B Aptalis Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 1 (Table of Contents)
Published: 24 Jan-2014
DOI: 10.3833/pdr.v2014.i1.2002 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
To help offset revenue losses following the 2012 patent expiry of its antidepressant Lexapro® (escitalopram), Forest Laboratories has agreed to acquire speciality pharmaceutical company Aptalis from its shareholders, including investment firm TPG, for US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS